Select Publications
Dang CT et al. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). Proc ASCO 2008;Abstract 518.
Gnant M et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc ASCO 2008;Abstract LBA4.
Norton L, Massagué J. Is cancer a disease of self-seeding? Nat Med 2006;12(8):875-8. No abstract available
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Smith I et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract
Untch M et al; HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19(6):1090-6. Abstract
EDITOR
Neil Love, MD
Paul E Goss, MD, PhD
- Select publications
Martine J Piccart-Gebhart,
MD, PhD
- Select publications
TUMOR PANEL CASE DISCUSSION
- Select publications
INTERVIEWS (continued)
Erica L Mayer, MD, MPH
- Select publications
Maria Theodoulou, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity